Abstract
Vaccinations are often the most effective tool against some disease known to mankind. This study offers a literature review on the role of vaccines regarding the risk of developing multiple sclerosis (MS) and MS relapse. The method used in this study is a systematic literature review on the database PubMed. The study found no change in risk of developing multiple sclerosis (MS) after vaccination against hepatitis B virus, human papillomavirus, seasonal influenza, measles–mumps–rubella, variola, tetanus, Bacillus Calmette-Guérin (BCG), polio, or diphtheria. No change in risk of relapse was found for influenza. Further research is needed for the potential therapeutic use of the BCG vaccine in patients in risk of developing MS and for the preventive potential of the tetanus and diphtheria vaccine.
Similar content being viewed by others
References
Denis F, Levy-Bruhl D (2006) Mass vaccination against hepatitis B: the French example. Curr Top Microbiol Immunol 304:115–129
Williamson EM, Berger JR (2015) Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs 29(3):229–244
Demicheli V et al (2003) Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. J Viral Hepat 10(5):343–344
DeStefano F, Verstraeten T, Chen RT (2002) Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines 1(4):461–466
Farez MF, Correale J (2011) Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 258(7):1197–1206
Gout O (2001) Vaccinations and multiple sclerosis. Neurol Sci 22(2):151–154
Jefferson T, Heijbel H (2001) Demyelinating disease and hepatitis B vaccination: is there a link? Drug Saf 24(4):249–254
Loebermann M et al (2011) Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol 8(3):143–151
Merelli E, Casoni F (2000) Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B. Neurol Sci 21(4 Suppl 2):S853–S856
Sievers EJ, Heyneman CA (2002) Relationship between vaccinations and multiple sclerosis. Ann Pharmacother 36(1):160–162
Ascherio A et al (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344(5):327–332
DeStefano F et al (2003) Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 60(4):504–509
Eftekharian MM et al (2014) Multiple sclerosis and immunological-related risk factors: results from a case-control study. Hum Antibodies 23(1–2):31–36
Geier DA, Geier MR (2005) A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 38(4):295–301
Hernan MA et al (2004) Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 63(5):838–842
Hocine MN et al (2007) Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. Vaccine 25(31):5938–5943
Langer-Gould A et al (2014) Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol 71(12):1506–1513
Mikaeloff Y et al (2007) Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain 130(Pt 4):1105–1110
Mikaeloff Y et al (2007) Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 161(12):1176–1182
Mikaeloff Y et al (2009) Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 72(10):873–880
Ozakbas S et al (2006) Development of multiple sclerosis after vaccination against hepatitis B: a study based on human leucocyte antigen haplotypes. Tissue Antigens 68(3):235–238
Ramagopalan SV et al (2009) Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology 32(4):257–262
Sadovnick AD, Scheifele DW (2000) School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 355(9203):549–550
Touze E et al (2002) Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 21(4):180–186
Zipp F, Weil JG, Einhaupl KM (1999) No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 5(9):964–965
Confavreux C et al (2001) Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 344(5):319–326
Chao C et al (2012) Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 271(2):193–203
Grimaldi-Bensouda L et al (2014) Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 275(4):398–408
Pellegrino P et al (2013) No evidence of a link between multiple sclerosis and the vaccine against the human papillomavirus. Eur J Epidemiol 28(8):705–707
Scheller NM et al (2015) Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 313(1):54–61
Alter M, Speer J (1968) Clinical evaluation of possible etiologic factors in multiple sclerosis. Neurology 18(2):109–116
Bardage C et al (2011) Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. Bmj 343:d5956
Zorzon M et al (2003) Risk factors of multiple sclerosis: a case-control study. Neurol Sci 24(4):242–247
Auriel E et al (2012) Seasonal and H1N1v influenza vaccines in MS: safety and compliance. J Neurol Sci 314(1–2):102–103
Bamford CR, Sibley WA, Laguna JF (1978) Swine influenza vaccination in patients with multiple sclerosis. Arch Neurol 35(4):242–243
De Keyser J, Zwanikken C, Boon M (1998) Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 159(1):51–53
Farez MF et al (2012) H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study. Mult Scler 18(2):254–256
McNicholas N, Chataway J (2011) Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J Neurol 258(8):1545–1547
Michielsens B et al (1990) Serial magnetic resonance imaging studies with paramagnetic contrast medium: assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. Eur Neurol 30(5):258–259
Miller AE et al (1997) A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48(2):312–314
Mokhtarian F et al (1997) Influenza virus vaccination of patients with multiple sclerosis. Mult Scler 3(4):243–247
Moriabadi NF et al (2001) Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 56(7):938–943
Myers LW et al (1977) Swine influenza virus vaccination in patients with multiple sclerosis. J Infect Dis 136(Suppl):S546–S554
Salvetti M et al (1995) Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol 242(3):143–146
Sibley WA, Bamford CR, Laguna JF (1976) Influenza vaccination in patients with multiple sclerosis. JAMA 236(17):1965–1966
Sibley WA, Foley JM (1965) Infection and immunization in multiple sclerosis. Ann N Y Acad Sci 122:457–466
Ahlgren C et al (2009) A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. Eur J Epidemiol 24(9):541–552
Bansil S et al (1997) Multiple sclerosis in India: a case-control study of environmental exposures. Acta Neurol Scand 95(2):90–95
Kurtzke JF et al (1997) Multiple sclerosis in the Faroe Islands. 7. Results of a case control questionnaire with multiple controls. Acta Neurol Scand 96(3):149–157
Pekmezovic T, Jarebinski M, Drulovic J (2004) Childhood infections as risk factors for multiple sclerosis: Belgrade case-control study. Neuroepidemiology 23(6):285–288
Zilber N, Kahana E (1996) Risk factors for multiple sclerosis: a case-control study in Israel. Acta Neurol Scand 94(6):395–403
Ahlgren C et al (2009) Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. Acta Neurol Scand 119(5):313–320
Andersen E, Isager H, Hyllested K (1981) Risk factors in multiple sclerosis: tuberculin reactivity, age at measles infection, tonsillectomy and appendectomy. Acta Neurol Scand 63(2):131–135
Casetta I et al (1994) Environmental risk factors and multiple sclerosis: a community-based, case-control study in the province of Ferrara, Italy. Neuroepidemiology 13(3):120–128
Compston DA et al (1986) Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 109(Pt 2):325–344
Berr C et al (1989) Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrenees, France. Acta Neurol Scand 80(1):46–50
Ristori G et al (1999) Use of Bacille Calmette–Guerin (BCG) in multiple sclerosis. Neurology 53(7):1588–1589
Farez MF, Correale J (2011) Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 68(10):1267–1271
Baumhackl U et al (2003) A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. Vaccine 21(Suppl 1):S56–S61
Quast U, Herder C, Zwisler O (1991) Vaccination of patients with encephalomyelitis disseminata. Vaccine 9(4):228–230
Ristori G et al (2014) Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology 82(1):41–48
Pool V, Gordon DM, Decker M (2012) Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow fever vaccination. Arch Neurol 69(1):144 (author reply 144-5)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Mailand, M.T., Frederiksen, J.L. Vaccines and multiple sclerosis: a systematic review. J Neurol 264, 1035–1050 (2017). https://doi.org/10.1007/s00415-016-8263-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-016-8263-4